The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough

[1]  I. Pavord,et al.  Demographic, Clinical, and Patient-Reported Outcome Data From Two Global, Phase 3 Trials of Chronic Cough. , 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  S. Birring,et al.  Chronic cough: new insights and future prospects , 2021, European Respiratory Review.

[3]  S. Birring,et al.  Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study , 2021, The European respiratory journal.

[4]  I. Pavord,et al.  Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough , 2020, ERJ Open Research.

[5]  K. Chung,et al.  Pharmacotherapeutic Options for Chronic Refractory Cough. , 2020, Expert opinion on pharmacotherapy.

[6]  S. Birring,et al.  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. , 2020, The Lancet. Respiratory medicine.

[7]  S. Birring,et al.  ERS guidelines on the diagnosis and treatment of chronic cough in adults and children , 2019, European Respiratory Journal.

[8]  A. Shields,et al.  Informing a priori Sample Size Estimation in Qualitative Concept Elicitation Interview Studies for Clinical Outcome Assessment Instrument Development. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  S. Birring,et al.  Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. , 2016, Chest.

[10]  Gary Layton,et al.  P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study , 2015, The Lancet.

[11]  A. Morice,et al.  The global epidemiology of chronic cough in adults: a systematic review and meta-analysis , 2015, European Respiratory Journal.

[12]  S. Birring,et al.  Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[13]  N. Leidy,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Elizabeth Molsen,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  I. Pavord,et al.  Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial , 2010, Thorax.

[16]  L. Nelsen,et al.  Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measure , 2010, Therapeutic advances in respiratory disease.

[17]  Sally J. Singh,et al.  Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) , 2003, Thorax.

[18]  K. Fletcher,et al.  Evaluation of a cough-specific quality-of-life questionnaire. , 2002, Chest.

[19]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..